Kura Oncology Inc (NASDAQ:KURA) insider Antonio Gualberto sold 18,000 shares of the stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $21.11, for a total transaction of $379,980.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Kura Oncology stock traded down $0.32 during mid-day trading on Friday, hitting $20.15. 332,873 shares of the stock were exchanged, compared to its average volume of 257,104. Kura Oncology Inc has a twelve month low of $10.20 and a twelve month high of $22.00. The company has a market cap of $796.91 million, a PE ratio of -11.72 and a beta of 2.51. The stock has a 50-day moving average of $18.35. The company has a quick ratio of 13.80, a current ratio of 13.80 and a debt-to-equity ratio of 0.05.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.08. As a group, equities research analysts expect that Kura Oncology Inc will post -1.71 earnings per share for the current year.
A number of brokerages recently commented on KURA. BidaskClub cut shares of Xperi from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 19th. Zacks Investment Research cut shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Citigroup set a $27.00 price objective on shares of PhaseBio Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 24th. HC Wainwright set a $31.00 price objective on shares of Kura Oncology and gave the company a “buy” rating in a research note on Wednesday, May 8th. Finally, ValuEngine raised shares of United Overseas Bank from a “sell” rating to a “hold” rating in a research note on Monday, June 17th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $28.00.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Further Reading: Are analyst ratings accurate?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.